The pretreatment albumin-globulin ratio can independently predict survival outcomes in patients with urothelial carcinoma.
Researchers identified the top reason why some patients with urothelial carcinoma don't pursue treatment.
Shilpa Gupta, MD, discusses recent developments in targeted molecular therapeutics for advanced bladder cancer.
Enfortumab vedotin plus pembrolizumab led to an ORR of 73.3% in cisplatin-ineligible patients with urothelial cancer.
The RACE IT trial finds neoadjuvant radio-immunotherapy followed by radical cystectomy a safe and feasible treatment option.
Metabolites were shown to have “the highest potential for differences between urine levels in healthy and BC patients."
Researchers developed a model to predict bladder cancer recurrence by combining microRNA with a pathological factor.
Smoking increased risk of urothelial carcinoma “more than expected” in patients with certain genetic risk factors.
Gemcitabine chemotherapy is effective at lowering the risk of recurrence in NMIBC, but development of resistance can occur.
A meta-analysis evaluated the safety of laparoscopic radical cystectomy surgical therapy in patients with bladder cancer.
Alternative splicing events in patients with BLCA suggests a potential role of AS events in prognosis and immunotherapy.
MMC administration within one day of surgery can reduce the risk of recurrence after removal of a bladder tumor for NMIBC.
The variables used to develop the prognostic nomogram included summary stage, tumor size, chemotherapy, and nodes examined.
PLSWT7-DMI has been reported to be a safe approach for the improved detection of bladder cancer and thorough resection.
CTCs and CECs “may putatively guide in diagnosis, prognosis prediction, and therapeutic decision-making for bladder ...
Laparoscopic surgeries that included holmium laser-guided mucosal incisions down to the perivesical fat were analyzed.